Pembrolizumab for metastatic adrenocortical carcinoma with high mutational burden: Two case reports

RATIONALE: In the setting of metastatic or locally advanced adrenocortical carcinoma, a limited number of therapies are available and their efficacy is generally below modest. The backbone of treatment remains surgery, even for metastatic disease, whenever it is possible, and mitotane. Chemotherapy...

Descripción completa

Detalles Bibliográficos
Autores principales: Mota, Jose Mauricio, Sousa, Luana Guimarães, Braghiroli, Maria Ignez, Siqueira, Luiz Tenório, Neto, João Evangelista Bezerra, Chapchap, Paulo, Hoff, Ana A. de Oliveira, Hoff, Paulo M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6314733/
https://www.ncbi.nlm.nih.gov/pubmed/30593126
http://dx.doi.org/10.1097/MD.0000000000013517

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6314733/
https://www.ncbi.nlm.nih.gov/pubmed/30593126
http://dx.doi.org/10.1097/MD.0000000000013517

Ejemplares similares